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Sir,
The majority of patients with hormone sensitive prostate cancer
become hormone refractory over time. Recently, Shamash et al
(2005) reported on the reinduction of hormone-sensitivity in
androgen refractory prostate cancer patients following chemother-
apy with lomustine and chlorambucil. In their prospective study,
eight out of 17 (47%) patients who were rechallenged with
hormonal therapy following the failure of chemotherapy had a
prostate specific antigen (PSA) response. Interestingly, 50% (four
out of eight) of the patients responded to rechallenge with
diethylstillboestrol (DES). We have had a similar experience in two
patients following chemotherapy with docetaxel and prednisolone.
PATIENT A
A 66-year-old man presented with acute urinary retention in July
2002 with a PSA of 125mgl
1 and was diagnosed with a Gleason 8
adenocarcinoma of the prostate. The PSA fell to 9.9mgl
1 after
commencing indefinite Goserelin 10.8mg implants; cyproterone
acetate (CPA 100mg tds) was started 21 months later on PSA
relapse (see Figure 1). In December 2004, the patient was admitted
with painful swelling of his left leg with an ultrasound Doppler
excluding a deep-vein thrombosis but a CT scan showed
significant left pelvic lymphadenopathy. The PSA had once again
relapsed so the CPA was changed to DES (1mg daily) with aspirin
(75mg daily) – the PSA initially decreased then remained stable for
12 months. In January 2006, prednisolone (10mg daily) was
unsuccessfully tried following further PSA increase and so the
patient was given chemotherapy with docetaxel and prednisolone.
On completion of six cycles in August 2006, the prednisolone was
continued with the addition of cyclophosphamide (50mg daily).
Megace was unsuccessfully trialled in December 2006, following
further relapse. In February 2007, the patient was rechallenged
with DES leading to a marked and sustained response with the PSA
falling from 420mgl
1 to the most recent value of 112mgl
1 six
months later.
PATIENT B
A 72-year-old man presented in February 2002 with a PSA
of 824mgl
1 and was diagnosed with a Gleason score 10,
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Figure 1 The PSA response to treatment in patients A and B. C
(cyproterone acetate 100mg tds); Cy (cyclophosphamide 50mg daily); D
(diethylstilboestrol 1mg daily); DP (docetaxel and prednisolone 10mg daily);
K (ketoconazole and hydrocortisone); L (LHRH agonist – Goserelin 10.8mg);
Me (megace); Mi (mitozantrone started); P (prednisolone 10mg daily). Published online 8 January 2008
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www.bjcancer.combone-scan-positive adenocarcinoma of the prostate. The PSA
fell to a nadir of 0.5mgl
1 after starting indefinite goserelin
implants, with cyproterone acetate (50mg daily) later prescribed
for hot flushes. In Spring 2003, the patient had a subtotal
colectomy for T3N0M0 colon carcinoma that did not require
any adjuvant treatment. In 2004, DES was started following
hormone relapse, but the PSA continued to progress. After
palliative radiotherapy to the spine, the patient received docetaxel
and prednisolone chemotherapy with a good clinical and
biochemical response. Six cycles of chemotherapy were completed
by January 2006 and the patient maintained on prednisolone
(10mg daily). A single high PSA in February 2006 was thought to
be secondary to acute urinary retention and subsequent catheter
insertion. Following further PSA relapse, the patient completed six
cycles of mitozantrone chemotherapy, and then subsequently
failed to tolerate ketoconazole and hydrocortisone. Most recently,
the PSA has fallen from 2333 to 1244mgl
1 following rechallenge
with DES.
DISCUSSION
A criticism of the study by Shamash et al (2005), is that the
patients were not androgen suppressed during chemotherapy, and
therefore responses to the reinduction of hormone therapy may
have been due to the growth of androgen-dependent clones.
However, two patients with a previous orchidectomy, and there-
fore castrate during chemotherapy, responded to rechallenge with
DES in their study. Our two patients described above, continued
androgen suppressive therapy throughout their treatment and this
suggests that DES may also have an androgen-independent
mechanism of action (Pienta and Bradley, 2006).
Chemotherapy with docetaxel and prednisolone has now become
the standard treatment for hormone refractory prostate cancer
(Tannock et al, 2004). There are currently no standard treatment
options for patients after the failure of docetaxel (Berthold et al,
2005). Based on our experience and that of Shamasa et al,w es u g g e s t
that rechallenge with DES is a worthwhile option for androgen-
refractory prostate cancer patients relapsing after chemotherapy.
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